Sergey Diakov
⬤ HIMS stock has dropped sharply over the past nine months, falling from highs near $70 to around $14.52 as of the latest monthly close. Selling pressure has been tied to an SEC probe, ongoing lawsuits, and a string of analyst downgrades. The monthly chart of Hims & Hers Health on the NYSE tells the story clearly - the stock has sliced through major intermediate levels, leaving it looking vulnerable at current prices.
⬤ Zooming out to the long-term chart, HIMS peaked near elevated price bands in 2024 and early 2025 before rolling into a sustained downtrend, printing a sequence of lower highs and lower lows. The most recent candle underlines just how aggressive the selling has been. The stock is now pressing against multi-year support in the mid-teens, a zone that held the price together back in 2021 and early 2022. Prior Tradable coverage flagged similar warning signs: testing critical support after extended losses, then sliding toward the $13.5 support area as the downtrend deepens - each piece pointing to growing structural stress around key price floors.
⬤ Regulatory scrutiny and legal developments have added fuel to the selloff. Investigations, rating cuts, and litigation have all piled on at once, accelerating the move down from peak levels. The chart captures that damage - lower highs forming after the top, followed by a pronounced push into 2026 lows. As analysts noted in earlier coverage, revisiting key 2021 support following a sharp decline signals just how far sentiment has shifted since the highs.
⬤ The HIMS retracement is a reminder of how fast momentum can unravel when regulatory and legal headwinds collide with technical breakdowns. With shares sitting near historically significant support on the monthly timeframe, the key question now is whether buyers step in to stabilize price action - or whether the broader downtrend keeps the pressure on.
Sergey Diakov
